Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertuzumab-dpzb + trastuzumab-strf + docetaxel
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Poherdy + Hercessi + docetaxel is a combination regimen consisting of two biosimilar monoclonal antibodies and a taxane chemotherapy agent, used for the treatment of HER2-positive breast cancer. Poherdy (pertuzumab-dpzb) is an interchangeable biosimilar to Perjeta (pertuzumab) that targets subdomain II of the human epidermal growth factor receptor 2 (HER2), preventing HER2 heterodimerization with other HER family receptors. Hercessi (trastuzumab-strf) is a biosimilar to Herceptin (trastuzumab) that binds to subdomain IV of HER2, inhibiting ligand-independent HER2 signaling. Docetaxel is a microtubule inhibitor that promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest and apoptosis. Together, the dual HER2 blockade by pertuzumab-dpzb and trastuzumab-strf, combined with the cytotoxic effects of docetaxel, provides synergistic anti-tumor activity and enhances antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing cancer cells. This regimen is indicated for the neoadjuvant, adjuvant, and first-line metastatic treatment of HER2-positive breast cancer.
- Brand names
- HANBEIYOU + HANQUYOU + docetaxelPoherdy + Hercessi + docetaxelPoherdy + Zercepac + docetaxel
- Other names
- THPTHP regimenpertuzumab + trastuzumab + docetaxel
02
Targets
EGFR (Epidermal growth factor receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pertuzumab-dpzb + trastuzumab-strf + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertuzumab-dpzb + trastuzumab-strf + docetaxel.